UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:
hello world
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
